Histopathological effects of preoperative chemoradiotherapy for pancreatic cancer: An analysis for the impact of radiation and gemcitabine doses

被引:28
作者
Hirata, Takero [1 ,4 ]
Teshima, Teruki [1 ]
Nishiyama, Kinji [1 ]
Ogawa, Kazuhiko [4 ]
Otani, Keisuke [1 ,4 ]
Kawaguchi, Yoshifumi [1 ]
Konishi, Koji [1 ]
Tomita, Yasuhiko [2 ]
Takahashi, Hidenori [3 ]
Ohigashi, Hiroaki [3 ]
Ishikawa, Osamu [3 ]
机构
[1] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Radiat Oncol, Osaka 5378511, Japan
[2] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Pathol, Osaka 5378511, Japan
[3] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Surg, Osaka 5378511, Japan
[4] Osaka Univ, Grad Sch Med, Dept Radiat Oncol, Osaka, Japan
关键词
Pancreatic cancer; Preoperative chemoradiotherapy; Gemcitabine; Histopathological effects; PHASE-II TRIAL; RESECTABLE ADENOCARCINOMA; NEOADJUVANT THERAPY; DUCTAL ADENOCARCINOMA; CHEMORADIATION; SURVIVAL; CHEMOTHERAPY; RESECTION; PANCREATICODUODENECTOMY; INVASION;
D O I
10.1016/j.radonc.2015.01.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and purpose: Histopathological findings of patients who underwent resection for pancreatic adenocarcinoma (PC) after preoperative chemoradiotherapy (CRT) reportedly showed beneficial effects. The purpose of our study was to evaluate the correlation between histopathological effects (HE) of preoperative CRT and treatment parameters [radiation and gemcitabine (GEM) doses]. Material and methods: HE of CRT were assessed on 158 primary lesions of 157 patients with PC who underwent pancreatic resection after preoperative CRT with GEM between January 2006 and December 2011. The radiation dose delivered to the primary tumor site and surrounding regional nodal areas was 50 Gy until September 2009 followed by the dose escalation. of a 10 Gy boost added for delivery with the field-in-field technique to the roots of the celiac and superior mesenteric arteries. Intravenous administration of GEM (1000 mg/m(2)) was initiated concurrently on days 1, 8, and 15, every 4 weeks and generally repeated for 3 cycles. HE of CRT on the primary tumor were categorized based on the number of tumor cells destroyed. Results: The median overall survival time was 74.5 months and 3-year and 5-year survival rates were 64.3% and 54.5%, respectively. Dose-volume parameters of radiation such as D33 with a cut-off value of 51.6 Gy were correlated significantly with HE (p = .0230). Lesions having received GEM >7625 mg/m(2) before surgical resection more frequently showed positive HE (p = .0002). Multivariate logistic regression analysis demonstrated that both 033 and cumulative GEM dose were significant predictors of definite HE (p = .0110 and <.0001, respectively). Conclusions: Our retrospective analysis showed that dose intensity of radiation and GEM is significantly related to HE of preoperative CRT for PC. (C) 2015 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 114 (2015) 122-127
引用
收藏
页码:122 / 127
页数:6
相关论文
共 48 条
[11]   Radiation dose ≥54 Gy and CA 19-9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation [J].
Golden, Daniel W. ;
Novak, Caroline J. ;
Minsky, Bruce D. ;
Liauw, Stanley L. .
RADIATION ONCOLOGY, 2012, 7
[12]   Caveolin-1 mediated radioresistance of 3D grown pancreatic cancer cells [J].
Hehlgans, Stephanie ;
Eke, Iris ;
Storch, Katja ;
Haase, Michael ;
Baretton, Gustavo B. ;
Cordes, Nils .
RADIOTHERAPY AND ONCOLOGY, 2009, 92 (03) :362-370
[13]   Meta-analysis of randomized trials: Evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer [J].
Heinemann, Volker ;
Boeck, Stefan ;
Hinke, Axel ;
Labianca, Roberto ;
Louvet, Christophe .
BMC CANCER, 2008, 8 (1)
[14]   Prospective phase II trial of Neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head [J].
Heinrich, Stefan ;
Pestalozzi, Bernhard C. ;
Schaefer, Markus ;
Weber, Achim ;
Bauerfeind, Peter ;
Knuth, Alexander ;
Clavien, Pierre-Alain .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15) :2526-2531
[15]   Long-term results of full-dose gemcitabine with radiation therapy compared to 5-fluorouracil with radiation therapy for locally advanced pancreas cancer [J].
Huang, Jiayi ;
Robertson, John M. ;
Margolis, Jeffrey ;
Balaraman, Savitha ;
Gustafson, Gary ;
Khilanani, Prem ;
Nadeau, Laura ;
Jury, Robert ;
McIntosh, Bruce .
RADIOTHERAPY AND ONCOLOGY, 2011, 99 (02) :114-119
[16]  
Japan Pancreas Society, 2011, Classification of pancreatic carcinoma, V3
[17]   Japanese classification of gastric carcinoma: 3rd English edition [J].
Sano T. ;
Kodera Y. .
GASTRIC CANCER, 2011, 14 (02) :101-112
[18]   Phase I-II trial of twice-weekly gemcitabine and concomitant irradiation in patients undergoing pancreaticoduodenectomy with extended lymphadenectomy for locally advanced pancreatic cancer [J].
Joensuu, TK ;
Kiviluoto, T ;
Kärkkäinen, P ;
Vento, P ;
Kivisaari, L ;
Tenhunen, M ;
Westberg, R ;
Elomaa, I .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (02) :444-452
[19]   Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators [J].
Katz, Matthew H. G. ;
Fleming, Jason B. ;
Bhosale, Priya ;
Varadhachary, Gauri ;
Lee, Jeffrey E. ;
Wolff, Robert ;
Wang, Huamin ;
Abbruzzese, James ;
Pisters, Peter W. T. ;
Vauthey, Jean-Nicolas ;
Charnsangavej, Chusilp ;
Tamm, Eric ;
Crane, Christopher H. ;
Balachandran, Aparna .
CANCER, 2012, 118 (23) :5749-5756
[20]   Neoadjuvant therapy for resectable and borderline resectable pancreatic cancer [J].
Kumar, Rachit ;
Jabbour, Salma K. .
JOURNAL OF RADIATION ONCOLOGY, 2013, 2 (04) :353-367